Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Treilleux

Showing results (131-140 of 186) with videos related to

Pageof 19
Sort By:
Journal of Personalized Medicine|April 23, 2022
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3Christelle de la Fouchardière, Pia Gamradt, Sylvie Chabaud, et al.
Breast Cancer (Dove Medical Press)|May 4, 2023
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective StudyBenoîte Mery, Christine Ménétrier-Caux, Laure Montané, et al.
Acta Neuropathologica|January 5, 2018
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degenerationMathilde Small, Isabelle Treilleux, Coline Couillault, et al.
Histopathology|November 21, 2023
Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfallsMadalena Souto Moura, João Costa, Valérie Velasco, et al.
Oral Oncology|May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trialThibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Clinical & Translational Immunology|February 22, 2020
CD163<sup>+</sup> tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytesRodrigo Nalio Ramos, Céline Rodriguez, Margaux Hubert, et al.
Bulletin Du Cancer|April 12, 2023
[Treatments for rare ovarian tumors: What's new?]Coriolan Lebreton, Stanislas Quesada, Marta Bini, et al.
Bulletin Du Cancer|October 8, 2023
[Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours]Sabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, et al.
Gynecologic Oncology|September 16, 2022
Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors GroupSabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, et al.
JAMA Oncology|May 13, 2022
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical TrialPierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, et al.
Pageof 19

Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
Journal of Personalized Medicine|April 23, 2022
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3Christelle de la Fouchardière, Pia Gamradt, Sylvie Chabaud, et al.
Breast Cancer (Dove Medical Press)|May 4, 2023
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective StudyBenoîte Mery, Christine Ménétrier-Caux, Laure Montané, et al.
Acta Neuropathologica|January 5, 2018
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degenerationMathilde Small, Isabelle Treilleux, Coline Couillault, et al.
Histopathology|November 21, 2023
Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfallsMadalena Souto Moura, João Costa, Valérie Velasco, et al.
Oral Oncology|May 13, 2026
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trialThibault Gauduchon, Laurence Digue, Céline Ferlay, et al.
Clinical & Translational Immunology|February 22, 2020
CD163<sup>+</sup> tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytesRodrigo Nalio Ramos, Céline Rodriguez, Margaux Hubert, et al.
Bulletin Du Cancer|April 12, 2023
[Treatments for rare ovarian tumors: What's new?]Coriolan Lebreton, Stanislas Quesada, Marta Bini, et al.
Bulletin Du Cancer|October 8, 2023
[Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours]Sabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, et al.
Gynecologic Oncology|September 16, 2022
Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors GroupSabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, et al.
JAMA Oncology|May 13, 2022
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical TrialPierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, et al.
Pageof 19